Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

S.E.J. van de Berg, P.T. Pelzer*, A.J. van der Land, E. Abdrakhmanova, A.M. Ozi, M. Arias, S. Cook-Scalise, G. Dravniece, A. Gebhard, S. Juneja, R. Handayani, D. Kappel, M. Kimerling, I. Koppelaar, S. Malhotra, B. Myrzaliev, B. Nsa, J. Sugiharto, N. Engel, C. MulderS. van den Hof

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number1404
Number of pages13
JournalBMC Public Health
Issue number1
Publication statusPublished - 16 Jul 2021


  • BPaL
  • Pretomanid
  • XDR-TB
  • Novel TB regimen
  • Acceptability
  • Feasibility
  • Implementation

Cite this